{
    "SPADE_UN_11338": {
        "Clinical Information": [
            {
                "Medical use": "Burn infection, skin infection with multidrug-resistant pathogens",
                "Company": "Demegen",
                "Stage of Development": "Phase III",
                "Comments": "Formation of multimeric pores in bacterial cell wall, stimulation of apoptosis",
                "Clinical Trials": [
                    "Not listed"
                ]
            }
        ],
        "Patent Information": [
            {
                "Patent No": "US 7091185 B2",
                "Patent Link": "http://www.lens.org/lens/patent/US_7091185_B2",
                "Patent Type": "Granted Patent",
                "Publication Date": "2006-8-15",
                "Family Info": "US20050187151",
                "Patent Title": "Periodic antimicrobial peptides.",
                "Abstract": "One embodiment of the invention comprises a method of producing periodic peptides, which can have antimicrobial uses, and further comprises the peptides themselves. A preferred method comprises the synthesis of simple periodic peptides made from polymerizing identical monomer units of four or fewer amino acids, wherein the minimum length of active peptide is 15 or 16 residues and wherein the minimum percentage of cationic residues is at least 25%."
            }
        ],
        "Sequence Information": {
            "SPADE ID": "SPADE_UN_11338",
            "Peptide Name": "D2A21(Demegal, Provena)",
            "Sequence": "FAKKFAKKFKKFAKKFAKFAFAF",
            "Source": "a 22-residue αhelix peptide",
            "Target Organism": "The MCC(minimum cidal concentration of C. trachomatis) of peptide D2A21was 5 μM (18.32 μg/ml).The MCC of gel formulations containing 2% D2A21 was 0.2 mM (0.7 mg/ml).",
            "Reference": [
                "Antimicrobial peptides: therapeutic potential. Expert Opin. Pharmacother. (2006).",
                "In Vitro Microbicidal Activities of Cecropin Peptides D2A21 and D4E1 and Gel Formulations Containing 0.1 to 2% D2A21 against Chlamydia trachomatis.Antimicrob. Agents Chemother(2002).(PMID:11751108)",
                "Treatment of infected wounds with the antimicrobial peptide D2A21.JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE(2003)(PMID:12707542)"
            ],
            "Biological Activity": [
                "Antibacterial"
            ],
            "Frequent Amino Acids": "KFA",
            "Absent Amino Acids": "CDEGHILMNOPQRSTUVWY",
            "Basic Residues": 9,
            "Acidic Residues": 0,
            "Hydrophobic Residues": 14,
            "Polar Residues": 15,
            "Positive Residues": 9,
            "Negative Residues": 0,
            "Mass": 2775.42,
            "PI": 10.9,
            "Net Charge": 9,
            "Hydrophobicity": -0.08,
            "Similar Sequences": [
                {
                    "SPADE_ID": "SPADE_UN_01169",
                    "Similarity": 1.0,
                    "Sequence": "KFAKKFAKKFAKKFAK"
                },
                {
                    "SPADE_ID": "SPADE_UN_01170",
                    "Similarity": 1.0,
                    "Sequence": "KFAKKFAKKFAKKFAKKFAK"
                },
                {
                    "SPADE_ID": "SPADE_UN_01171",
                    "Similarity": 1.0,
                    "Sequence": "KFAKKFAKKFAKKFAKKFAKKFAK"
                }
            ]
        }
    }
}